GlassScriptPhysician profile
Gemma Beauchamp
NPI 1578339057
$1,537.65
in general payments reported to CMS, 2019-2025
13 companies · $699 in 2025
The $699 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $738 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $258.03 | 2024-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $217.03 | 2024-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Rexulti |
| Gilead Sciences, INC. | $125.00 | 2024 | Descovy |
| Avadel Cns Pharmaceuticals, LLC | $125.00 | 2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $120.00 | 2024 | |
| Dexcom, INC. | $106.64 | 2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $100.86 | 2023 | Dupixent |
| Mallinckrodt Hospital Products INC. | $100.00 | 2025 | Acthar |
| Pulmonx Corporation | $94.95 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Amgen INC. | $94.15 | 2024 | |
| Abbott Laboratories | $50.05 | 2025 | Cardiomems, Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $20.94 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gemma Beauchamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.